Analysis of the Cancer Genome Atlas (TCGA) reveals coamplification of RTKs, particularly EGFR and PDGFRA, in significant subpopulations of GBM cells, impacting therapeutic strategies.22 Distinct RTK-dependent subpopulations may contribute to poor responses to single-pathway inhibitors, advocating for alternative strategies like sequential therapies to minimize toxicity while targeting diverse tumor cell populations. This evidence concerns the gene PDGFRA and glioblastoma.